Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia
Yves Chalandon(University of Geneva), Hervé Dombret(University of London Institute in Paris), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse), Emmanuelle Tavernier(Institute Cancer De La Loire Lucien Neuwirth), Véronique Lhéritier(Hospices Civils de Lyon), Sébastien Maury(Assistance Publique – Hôpitaux de Paris), Norbert Ifrah(Institut National du Cancer), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Stéphane Leprêtre(Normandie Université), Mårina Lafage‐Pochitaloff(Inserm), Philippe Rousselot(Université Paris-Saclay), Sylvie Chevret(Saint Louis University Hospital), Emmanuel Raffoux(Inserm), Xavier Thomas(Hôpital Lyon Sud), Martine Escoffre‐Barbe(Université Rennes 2), Jean‐François Lambert(Centre Hospitalier Universitaire Vaudois), Céline Berthon(Université Paris-Sud), Jean‐Michel Cayuela(Inserm), Sandrine Hayette(Hôpital Claude Huriez), Claire Abbal(Centre Hospitalier Universitaire Vaudois)
Cited by 377
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k